Bristol-Myers Squibb

This clinical trial is testing whether a combination of two immunotherapy drugs, relatlimab and nivolumab, can help people with advanced colorectal cancer that has not responded to previous treatments. The study compares this combination to two standard chemotherapy options (rego…

This phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…

This phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…

This early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…

This study tested an experimental drug called MYK-224 in 18 adults with a type of heart disease that makes the heart muscle too thick and blocks blood flow. The goal was to see if the drug is safe and helps reduce symptoms. The trial was stopped early, so results are limited.

This study looked at the safety and effectiveness of the drug ozanimod for people with moderate to severe ulcerative colitis. It aimed to see if the drug could improve symptoms like diarrhea and rectal bleeding, and how it affected quality of life. The study was terminated early,…

This study tested whether combining two immunotherapy drugs (nivolumab and relatlimab) works better than nivolumab alone to keep melanoma from returning after surgical removal. It involved over 1,000 adults and teens with stage III or IV melanoma that had been completely removed.…

This early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose…

This phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …

This study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The …

This Phase 3 study tested the drug mavacamten in 580 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart muscle condition that makes it harder for the heart to pump blood. Participants received either mavacamten or a placebo. The study measured changes in…

This study tested the drug deucravacitinib (SOTYKTU) in 130 people with psoriasis on the palms, soles, and genitals. The goal was to see if it improves skin clearance and reduces symptoms. The trial was terminated early, so final results are limited.

This study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…

This study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.